Quantum Leap Healthcare Collaborative

Agent Information Sheet

Widely hailed as the future of phase II drug development, the adaptive I-SPY 2 platform trial has set a new benchmark for
Close
Close
I-SPY Trial Manuscript
<- Back to All Agents

Lynparza + Imfinzi

Trade Name:
Olaparib + Durvalumab
Company:
Status:
Currently Enrolling
Agent Chaperone(s):
Treatment Protocol:
Durvalumab is a human immunoglobulin monoclonal antibody (mAb). Olaparib is a Poly(ADP-ribose) polymerase (PARP) Inhibitor. Durvalumab is administered intravenously at 1500 mg once every 4 weeks (q4w) with Olaparib twice a day at 100 mg BID and Paclitaxel weekly at 80 mg/m2 for 12 total weeks. This regimen is followed by AC (q2w or q3w) for 4 weeks.
Date Entered I-SPY:
May 3, 2018
Date Left I-SPY:
No. Participants in Arm:
Graduating Subtypes:
tbd
Agent Description:
Notes:
Final pCR Probabilities:
Primary Manuscript:
 
abstractpdfview original